1.980USDMkt Cap: 266.43M USDP/E: —Last update: 2026-05-22
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeu…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap266.43M USD
Enterprise Value135.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-101.69M USD
Revenue/Share—
Last Price1.980 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees43
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.70
PEG—
EV/EBITDA-1.56
EV/Revenue—
P/S—
P/B1.77
EPS (TTM)-1.49
EPS (Forward)-0.54
52W Range
1.94550% of range2.015
52W High2.015 USD
52W Low1.945 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-391.42%
ROA-172.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.14M USD
CapEx (TTM)212.00K USD
FCF Margin—
FCF Yield-16.24%
Net Debt-131.81M USD
Net Debt/EBITDA1.51
Balance Sheet
Debt/Equity0.38
Current Ratio7.21
Quick Ratio6.95
Book Value/Sh1.125 USD
Cash/Share1.043 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)4.600 USD
Target Range4.000 USD – 6.000 USD
# Analysts5
Ownership
Shares Out.134.56M
Float107.02M
Insiders0.92%
Institutions73.47%
Short Interest
Short Ratio1.9d
Short % Float1.82%
Short % Out.1.64%
Shares Short2.21M
Short (prev mo.)2.22M
Technical
SMA 501.902 (+4.1%)
SMA 2001.609 (+23.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.17M
Avg Vol (10d)635.16K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—